Business Wire

TRON-DAO

Share
Justin Sun Wins the Bid for All "Twelve Digital Zodiac Heads"

TRON founder Justin Sun has recently purchased the complete set of the crypto artworks "Twelve Digital Zodiac Heads" at the Twelve Digital Zodiac Heads Special Auction hosted by Metapoly XM, a brand under Poly Auction (Xiamen).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220403005114/en/

The "Twelve Digital Zodiac Heads" is the one and only NFT art collection that draws inspiration from China's Zodiac Heads, which was purchased on March 31 at a hammer price of around ¥9,832,500. Shortly after the auction, Justin Sun stated to the public that he would donate this collection in the future for a broader audience to enjoy. It is also believed that one of the animal heads in this collection will soon be listed on APENFT Marketplace for auction and introduced as rare, special-breed horses into WIN NFT HORSE, a horse racing game co-launched by TRON, the APENFT Foundation, and WINKLink.

The twelve zodiac animals are an epitome of Chinese folk culture and the unique philosophy of the Chinese nation. According to traditional Chinese culture, every newborn is assigned an auspicious animal based on their birth year. These animals are unchangeable marks that follow each Chinese throughout their life. They serve as a bond to maintain the national feelings and the Chinese culture. And of all the physical embodiment of these symbols, the Twelve Old Summer Palace bronze heads are the most precious.

Gathering the twelve bronze heads in the metaverse marks another major endeavor made by digital technology, represented by blockchain, in the cultural and art sphere. In the context of social informatization and digitization, digital propagation and protection of traditional culture will embrace wider applications in order to reproduce time-honored artworks in the digital world and diversify people's experience in art appreciation.

As a trailblazer in digital technology, Justin Sun also has serious clout in the realm of top-notch art collections. Through clinching a myriad of artworks created both by art masters and emerging digital artists on major trading platforms, Justin has managed to build an empire incorporating art, investment, finance, and more. His collections include works by Pablo Picasso, Andy Warhol, Giacometti, Beeple, and Pak, the latter two being the two most valuable crypto artists worldwide. In addition, Justin Sun has donated a number of well-known works, including Le Nez and Femme nue couchée au collier(Marie-Thérèse) , to organizations such as the APENFT Foundation to support the development of digital art.

APENFT is backed by the underlying technology of top-notch blockchains TRON with support from the world's largest distributed storage system Bittorrent File System (BTFS), dedicated to promoting the creator economy and fostering the integration of finance, culture and art in Metaverse. Its APENFT Marketplace, based on the TRON, will also be launched shortly.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye